SC
XFOR icon

Stempoint Capital’s X4 Pharmaceuticals XFOR Stock Holding History

Stempoint Capital’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-850,742
Closed -$3.51M – 114
2026
Q1 		$3.51M Sell
850,742
-47,723
-5% -$179K 0.67% 43
2025
Q4 		$3.59M Buy
898,465
+343,054
+62% +$1.25M 0.62% 46
2025
Q3 		$1.9M Buy
+555,411
New +$1.43M 0.38% 51

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Stempoint Capital's XFOR Position: Q2 2026 in Review

Stempoint Capital sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 850,742 shares — an estimated $3.51M sold.

Stempoint Capital first reported a position in XFOR in Q3 2025 and held it in 3 quarters. The position peaked at $3.59M in Q4 2025. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Stempoint Capital reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Stempoint Capital sold 850,742 X4 Pharmaceuticals shares in Q2 2026, an estimated $3.51M.
  • Stempoint Capital first reported a position in X4 Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Stempoint Capital's X4 Pharmaceuticals position peaked at $3.59M in Q4 2025.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.